Close menu

September 7th, 2023 | 08:00 CEST

Biotech with tailwind - Newron Pharmaceuticals, Defence Therapeutics, BioNTech

  • Biotechnology
  • Pharma
Photo credits:

There is a lot of activity in the biotechnology sector, even though the broadly diversified Nasdaq Biotech Index reflects this with a performance of only 1% since the beginning of the year. In addition to the increasing number of acquisitions by Big Pharma, promising technologies from second-tier companies are performing extremely well. Furthermore, the surging COVID-19 statistics are instilling hope in vaccine producers as they aim to revive their slumping sales.

time to read: 3 minutes | Author: Stefan Feulner

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    BioNTech - Booster for the balance sheet

    BioNTech's half-yearly financial results proved disappointing following the significant decline in the COVID-19 pandemic and the return to normalcy. But right now, medical experts warn of another harsh Corona winter due to rising case numbers. Just in time, BioNTech and its US partner Pfizer are launching its vaccine adapted to the current Omicron variant XBB.1.5. The vaccine will be available in medical practices as early as September 18.

    The vaccine received approval by the European Medicines Agency (EMA) last week. According to the Standing Committee on Vaccination (STIKO), a booster is recommendable for all who are 60 years or older or belong to a high-risk group. This high-risk group includes anyone aged six months and older who is at particular risk for a severe course of COVID-19 as a result of an underlying medical condition. For healthy individuals aged between 18 and 59, Stiko recommends only a basic immunization consisting of three "immunological events."

    The Medicines and Healthcare products Regulatory Agency also gave its counterpart the green light. Like the other COVID vaccines, the vaccine is also marketed under the brand name Comirnaty and is licensed for use in individuals aged 6 months and older, the Medicines and Healthcare products Regulatory Agency (MHRA) said.

    After falling more than 45% to a one-year low of USD 95.50, BioNTech shares managed to start a countermovement in the overarching downtrend to a level of USD 125.83. The next broad resistance lies in the area of USD 128.75. In their current study, the analysts at Jefferies do not believe that the German biotech flagship has any further upside potential. Although the target was raised from USD 108 to USD 111, the target zone is around 9% below the current stock price.

    Defence Therapeutics increases visibility

    With a market capitalization of CAD 146.53 million, the Canadian biotech company is still largely unknown to the broader investor community despite its patented, scalable platform technology and diversified product portfolio. This year alone, for example, Defence Therapeutics expects to initiate two Phase I trials against cancer as well as crucial results from a comparative study around mRNA vaccine.

    The Canadian biotech company is focused on developing next-generation vaccines and ADC products using its proprietary and patented Accum™ technology. The technology has the distinct advantage of ensuring the precise transport of vaccine antigens or ADCs in an intact form to target cells, significantly improving efficiency and, thus, efficacy against diseases such as cancer or infectious diseases.

    To increase its reach and thereby raise awareness, Defence Therapeutics will be featured on the nationally broadcast knowledge show Viewpoint, hosted by actor Dennis Quaid. Viewpoint will showcase Defence Therapeutics' cutting-edge research activities, clinical trials and therapeutic biotechnology innovations to more than 170 television stations across the US on September 18, where it will be available as programming content for an entire year. In addition, Defence Therapeutics has produced a commercial to air nationally on the Fox Business Network during prime time on Thursday, September 7, 2023, and Sunday, September 10, 2023.

    Shares of the Vancouver-based company were able to regain the CAD 3.00 level after a month-long consolidation. If the resistance at CAD 3.30 is overcome, the annual high at CAD 4.85, marked in January, should be tested again.

    Newron Pharmaceuticals - Profit-taking after figures

    With a performance of 240%, the biopharmaceutical company, which focuses on novel therapies for diseases of the central and peripheral nervous system, clearly outperformed the benchmark. The Italians relied primarily on its hopeful Evenamide, which is about to start the approval-relevant Phase III trial. In this trial, Evenamide is to be used as an add-on therapy in patients suffering from treatment-resistant schizophrenia. In addition, the Company is also evaluating the compound in patients with chronic schizophrenia who have an inadequate response to their current antipsychotics but are not classified as treatment-resistant. Study 008A continues to enrol patients, with results expected between late 2023 and early 2024.

    With a solid cash cushion of EUR 17.1 million, development work should be secured well into 2024. In addition, Newron was able to show revenues from licensing income and revenue sharing of EUR 5.5 million in the first half of the year. This was offset by research and development costs of EUR 5.7 million. Administrative costs amounted to EUR 4.1 million. Below the line, the Italians published a loss of EUR 7.0 million.

    Several analyst firms have a positive outlook on the further development of the biotech company. In its recent study, Rx Securities issued a "Buy" rating with a price target of CHF 6.00. Meanwhile, Baader Helvea Equity Research estimates the fair value of Newron Pharmaceuticals at CHF 7.20, representing a potential upside of nearly 30% from the current price.

    The biotech sector is on the move. In addition to numerous acquisitions, smaller companies like Defence Therapeutics and Newron Pharmaceuticals are facing decisive months. The increase in Corona cases could boost the revenues of vaccine manufacturer BioNTech after a weak first half of the year.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author

    Related comments:

    Commented by André Will-Laudien on February 20th, 2024 | 07:30 CET

    Takeover fever in the biotech sector! Will MorphoSys now be followed by Defence Therapeutics, Evotec and Bayer?

    • Biotechnology
    • Pharma
    • Innovations

    It has happened: Novartis is bidding for MorphoSys. Once again, a long-lasting and persistent rumour mill eventually confirms itself. Those who remained loyal to MorphoSys despite heavy selling last fall have now made a profit of over 300%. If we turn the analytical magnifying glass on the sector, we can see that the speculative biotech stock market segment has started to move again since the challenging year 2023. Hopes of falling interest rates in the near future, along with several other M&A hopes, have led to steady inflows into listed bio-ETFs, resulting in fund managers having recently adjusted their weightings upwards. We analyze which stocks are currently making the loudest noise.


    Commented by André Will-Laudien on February 16th, 2024 | 07:00 CET

    MorphoSys and Cardiol Therapeutics in upward mode, while Bayer and Pfizer are in slow mode

    • Biotechnology
    • Pharma

    The biotech sector has made a very differentiated start to the new year. While the old favorites are barely moving, the second-line stocks MorphoSys and Cardiol Therapeutics are making a real splash. At Bayer, the bad news just won't go away, and despite a successful major takeover, Pfizer has not yet found its forward gear. After a rally of almost 15% in December, the Nasdaq Biotechnology Index (NBI) has taken a pause in the current year. Now, everyone is waiting for the first interest rate cut by central banks. Inflation is already falling, and the negative economic data for the Eurozone is increasing. The ECB would normally be in demand. What should investors urgently keep an eye on?


    Commented by Fabian Lorenz on February 14th, 2024 | 07:00 CET

    Plug Power, Bayer, Defense Metals: Shares in panic mode

    • Mining
    • RareEarths
    • Hydrogen
    • Pharma

    Is everything not so bad at Plug Power, after all? In January, the hydrogen specialist triggered panic among investors with an announced capital increase. Now, the CEO is suddenly rowing back. So, should one buy the stock now? One analyst advises caution. Bayer shareholders are also in panic mode. The downward trend of the share simply cannot find a bottom. Even at this level, analysts are cautious. Defense Metals, on the other hand, is benefiting from panic - because this concerns the supply of rare earths. The dependence on China is enormous. Defense Metals aims to change this with its rare earth project in Canada. The Company CEO expressed confidence in an interview, stating that an important agreement has been reached with the local population, and important dates are on the horizon.